Methylnaltrexone: all 59 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.RecruitingNCT06162377Phase 4
• Chronic Widespread Pain in HIV: Novel Mechanisms and TherapeuticsRecruitingNCT04787848Not applicable
• Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus PreventionCompletedNCT03852524Phase 2Results posted
• Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced ConstipationCompletedNCT03523520Phase 4Results posted
• Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With MorphineCompletedNCT02403830Phase 4Results posted
• Compassionate Use Study of MethylnaltrexoneCompletedNCT01368562Not applicableResults posted
• A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant PainCompletedNCT01186770Phase 3Results posted
• Effect of Methylnaltrexone on GI Transit in Healthy VolunteersCompletedNCT01055704Phase 4Results posted
• Methylnaltrexone for Opioid-induced Constipation in Cancer PatientsCompletedNCT01004393Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-ConstipationCompletedNCT00936884Phase 3Results posted
• Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced ConstipationCompletedNCT00804141Phase 3Results posted
• Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced IllnessCompletedNCT00672477Phase 4Results posted
• Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced IllnessCompletedNCT00672139Phase 4Results posted
• Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic ProceduresCompletedNCT00640146Phase 2Results posted
• Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant PainCompletedNCT00605644Phase 2Results posted
• Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant PainCompletedNCT00547586Phase 2Results posted
• Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant PainCompletedNCT00529087Phase 3Results posted
• A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia RepairCompletedNCT00528970Phase 3Results posted
• Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)CompletedNCT00401375Phase 3Results posted
• An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerWithdrawnNCT04151719Phase 3
• A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerWithdrawnNCT04083651Phase 2/3
• Opioid-Induced Swallowing Dysfunction - The Impact of Bolus VolumeStatus unknownNCT03283020Phase 4
• The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in HealthCompletedNCT03014843Not applicable
• Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI PatientsCompletedNCT02942550Phase 4
• Study of Methylnaltrexone in Opioid-Induced Constipation PatientsStatus unknownNCT02574819Phase 2/3
• Methylnaltrexone Pharmacokinetics in Neurointensive Care PatientsCompletedNCT01889290Phase 1
• Methylnaltrexone Use for Opioid-induced Postoperative ConstipationCompletedNCT01773096Phase 4
• Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy SubjectsCompletedNCT01596777Phase 1
• Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.CompletedNCT01596764Phase 1
• Safety and Gastrointestinal Effects of Intravenous MethylnaltrexoneCompletedNCT01367587Phase 2
• Naloxone and Intravenous Methylnaltrexone Effects on Bladder FunctionCompletedNCT01367561Phase 1
• Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative IleusCompletedNCT01367548Phase 2
• Effects of MNTX on CYP450 2D6 in Metabolizers of DextromethorphanCompletedNCT01367535Phase 1
• Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal FunctionCompletedNCT01367509Phase 1
• Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous DoseCompletedNCT01367496Phase 1
• Study of the Pharmacokinetics of Intravenous Administered 14C-MNTXCompletedNCT01367483Phase 1
• Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTXCompletedNCT01366378Phase 1
• Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone BromideCompletedNCT01366365Phase 1
• Tolerance and Pharmacokinetics Study of MNTX TabletsCompletedNCT01366339Phase 1
• Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult SubjectsCompletedNCT01366326Phase 1
• Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac RepolarizationCompletedNCT01363323Phase 1
• Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With OpiatesWithdrawnNCT01360372Phase 3
• Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill PatientsTerminatedNCT01117376Phase 2
• Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care UnitStatus unknownNCT01050595Phase 3
• Opioids and Esophageal FunctionCompletedNCT01012960Phase 4
• Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?WithdrawnNCT00949377Phase 4
• Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer SubjectsWithdrawnNCT00858754Phase 4
• Study Evaluating Oral MOA-728 in Subjects on Methadone TherapyWithdrawnNCT00505583Phase 1
• Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy SubjectsCompletedNCT00464802Phase 1
• Study Evaluating MOA-728 in Subjects on Stable Methadone MaintenanceCompletedNCT00447811Phase 1
• Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone SubjectsCompletedNCT00444158Phase 1
• Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy SubjectsCompletedNCT00434395Phase 1
• Study Evaluating MOA-728 Administered in Healthy MenWithdrawnNCT00427258Phase 1
• Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On MethadoneCompletedNCT00398502Phase 1
• Bioequivalence Study in Healthy VolunteersCompletedNCT00387985Phase 1
• Dose Ranging Study in Healthy Methadone Maintenance SubjectsCompletedNCT00387491Phase 1
• Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative IleusCompletedNCT00387309Phase 3
• Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant PainCompletedNCT00366431Phase 2
• Study Evaluating the Safety of MOA-728 Administered Orally to Healthy SubjectsCompletedNCT00311350Phase 1

← Methylnaltrexone overview